Try a new search

Format these results:

Searched for:

in-biosketch:true

person:segevd01

Total Results:

1181


6-mo Antibody Kinetics and Durability After 3 Doses of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

Abedon, Aura T; Alejo, Jennifer L; Kim, Jake D; Thomas, Letitia; Mitchell, Jonathan; Chiang, Teresa P Y; Avery, Robin K; Tobian, Aaron A R; Levan, Macey L; Warren, Daniel S; Massie, Allan B; Garonzik-Wang, Jacqueline M; Segev, Dorry L; Werbel, William A
PMID: 35066543
ISSN: 1534-6080
CID: 5127912

The Effect of Acuity Circles on Deceased Donor Transplant and Offer Rates Across Model for End-Stage Liver Disease Scores and Exception Statuses

Wey, Andrew; Noreen, Samantha; Gentry, Sommer; Cafarella, Matt; Trotter, James; Salkowski, Nicholas; Segev, Dorry; Israni, Ajay; Kasiske, Bertram; Hirose, Ryutaro; Snyder, Jon
Acuity circles (AC), the new liver allocation system, was implemented on February 4, 2020. Difference-in-differences analyses estimated the effect of AC on adjusted deceased donor transplant and offer rates across Pediatric End-Stage Liver Disease (PELD) and Model for End-Stage Liver Disease (MELD) categories and types of exception statuses. The offer rates were the number of first offers, top 5 offers, and top 10 offers on the match run per person-year. Each analysis adjusted for candidate characteristics and only used active candidate time on the waiting list. The before-AC period was February 4, 2019, to February 3, 2020, and the after-AC period was February 4, 2020, to February 3, 2021. Candidates with PELD/MELD scores 29 to 32 and PELD/MELD scores 33 to 36 had higher transplant rates than candidates with PELD/MELD scores 15 to 28 after AC compared with before AC (transplant rate ratios: PELD/MELD scores 29-32, 2.34 3.324.71 ; PELD/MELD scores 33-36, 1.70 2.513.71 ). Candidates with PELD/MELD scores 29 or higher had higher offer rates than candidates with PELD/MELD scores 15 to 28, and candidates with PELD/MELD scores 29 to 32 had the largest difference (offer rate ratios [ORR]: first offers, 2.77 3.955.63 ; top 5 offers, 3.90 4.394.95 ; top 10 offers, 4.85 5.305.80 ). Candidates with exceptions had lower offer rates than candidates without exceptions for offers in the top 5 (ORR: hepatocellular carcinoma [HCC], 0.68 0.770.88 ; non-HCC, 0.73 0.810.89 ) and top 10 (ORR: HCC, 0.59 0.650.71 ; non-HCC, 0.69 0.750.81 ). Recipients with PELD/MELD scores 15 to 28 and an HCC exception received a larger proportion of donation after circulatory death (DCD) donors after AC than before AC, although the differences in the liver donor risk index were comparatively small. Thus, candidates with PELD/MELD scores 29 to 34 and no exceptions had better access to transplant after AC, and donor quality did not notably change beyond the proportion of DCD donors.
PMID: 34482614
ISSN: 1527-6473
CID: 5127612

Cognitive Impairment and Physical Frailty in Patients With Cirrhosis

Berry, Kacey; Duarte-Rojo, Andres; Grab, Joshua D; Dunn, Michael A; Boyarsky, Brian J; Verna, Elizabeth C; Kappus, Matthew R; Volk, Michael L; McAdams-DeMarco, Mara; Segev, Dorry L; Ganger, Daniel R; Ladner, Daniela P; Shui, Amy; Tincopa, Monica A; Rahimi, Robert S; Lai, Jennifer C
Physical frailty and impaired cognition are common in patients with cirrhosis. Physical frailty can be assessed using performance-based tests, but the extent to which impaired cognition may impact performance is not well characterized. We assessed the relationship between impaired cognition and physical frailty in patients with cirrhosis. We enrolled 1,623 ambulatory adult patients with cirrhosis waiting for liver transplantation at 10 sites. Frailty was assessed with the liver frailty index (LFI; "frail," LFI ≥ 4.4). Cognition was assessed at the same visit with the number connection test (NCT); continuous "impaired cognition" was examined in primary analysis, with longer NCT (more seconds) indicating worse impaired cognition. For descriptive statistics, "impaired cognition" was NCT ≥ 45 seconds. Linear regression associated frailty and impaired cognition; competing risk regression estimated subhazard ratios (sHRs) of wait-list mortality (i.e., death/delisting for sickness). Median NCT was 41 seconds, and 42% had impaired cognition. Median LFI (4.2 vs. 3.8) and rates of frailty (38% vs. 20%) differed between those with and without impaired cognition. In adjusted analysis, every 10-second NCT increase associated with a 0.08-LFI increase (95% confidence interval [CI], 0.07-0.10). In univariable analysis, both frailty (sHR, 1.63; 95% CI, 1.43-1.87) and impaired cognition (sHR, 1.07; 95% CI, 1.04-1.10) associated with wait-list mortality. After adjustment, frailty but not impaired cognition remained significantly associated with wait-list mortality (sHR, 1.55; 95% CI, 1.33-1.79). Impaired cognition mediated 7.4% (95% CI, 2.0%-16.4%) of the total effect of frailty on 1-year wait-list mortality. Conclusion: Patients with cirrhosis with higher impaired cognition displayed higher rates of physical frailty, yet frailty independently associated with wait-list mortality while impaired cognition did not. Our data provide evidence for using the LFI to understand mortality risk in patients with cirrhosis, even when concurrent impaired cognition varies.
PMCID:8710786
PMID: 34558844
ISSN: 2471-254x
CID: 5127682

Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series [Letter]

Connolly, Caoilfhionn M; Chiang, Teresa Po-Yu; Boyarsky, Brian J; Ruddy, Jake A; Teles, Mayan; Alejo, Jennifer L; Massie, Allan; Werbel, William A; Shah, Ami A; Christopher-Stine, Lisa; Garonzik-Wang, Jacqueline; Segev, Dorry L; Paik, Julie J
PMID: 34556484
ISSN: 1468-2060
CID: 5127672

Antibody response to 2-dose SARS-CoV-2 mRNA vaccination in pediatric solid organ transplant recipients [Letter]

Qin, Caroline X; Auerbach, Scott R; Charnaya, Olga; Danziger-Isakov, Lara A; Ebel, Noelle H; Feldman, Amy G; Hsu, Evelyn K; McAteer, John; Mohammad, Saeed; Perito, Emily R; Thomas, Ashley M; Chiang, Teresa P Y; Garonzik-Wang, Jacqueline M; Segev, Dorry L; Mogul, Douglas B
PMCID:8653193
PMID: 34517430
ISSN: 1600-6143
CID: 5127652

Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series [Letter]

Connolly, Caoilfhionn M; Teles, Mayan; Frey, Sarah; Boyarsky, Brian J; Alejo, Jennifer L; Werbel, William A; Albayda, Jemima; Christopher-Stine, Lisa; Garonzik-Wang, Jacqueline; Segev, Dorry L; Paik, Julie J
PMID: 34493492
ISSN: 1468-2060
CID: 5127632

Life expectancy without a transplant for status 1A liver transplant candidates

Wood, Nicholas L; VanDerwerken, Douglas N; King, Elizabeth A; Segev, Dorry L; Gentry, Sommer E
Status 1A liver transplant candidates are given the highest medical priority for the allocation of deceased donor livers. Organ Procurement and Transplantation Network (OPTN) policy requires physicians to certify that a candidate has a life expectancy without a transplant of less than 7 days for that candidate to be given status 1A. Additionally, candidates receiving status 1A must have one of six medical conditions listed in policy. Using Scientific Registry of Transplant Recipients data from all prevalent liver transplant candidates from 2010 to 2020, we used a bias-corrected Kaplan-Meier model to calculate the survival of status 1A candidates and to determine their life expectancy without a transplant. We found that status 1A candidates have a life expectancy without a transplant of 24 (95% CI 20-46) days-over three times longer than what policy requires for status 1A designation. We repeated the analysis for subgroups of status 1A candidates based on the medical conditions that grant status 1A. We found that none of these subgroups met the life expectancy requirement. Harmonizing OPTN policy with observed data would sustain the integrity of the allocation process.
PMCID:8720063
PMID: 34487636
ISSN: 1600-6143
CID: 5127622

Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease

Frey, Sarah; Chowdhury, Reezwana; Connolly, Caoilfhionn M; Werbel, William A; Segev, Dorry L; Parian, Alyssa M; Tsipotis, Evangelos; Dudley-Brown, Sharon; Lazarev, Mark; Melia, Joanna M; Truta, Brindusa; Yu, Huimin; Selaru, Florin M
PMCID:8732901
PMID: 34998996
ISSN: 1542-7714
CID: 5127872

Waitlist outcomes for liver waitlist candidates 1-year following the implementation of MMAT/250 score [Meeting Abstract]

Ishaque, Tanveen; Beckett, James; Wang, Jacqueline; Karhadkar, Sunil; Segev, Dorry; Massie, Allan
ISI:000739470700004
ISSN: 1600-6135
CID: 5133482

Survival benefit of split liver transplantation for pediatric and adult candidates

Bowring, Mary G; Massie, Allan B; Schwarz, Kathleen B; Cameron, Andrew M; King, Elizabeth A; Segev, Dorry L; Mogul, Douglas B
Patient and graft survival are similar following whole versus split liver transplants (SLT) among pediatric and adult recipients, yet SLTs are rarely used. We sought to determine the survival benefit associated with accepting a splittable offer for SLT versus declining and waiting for a subsequent offer using 2010-2018 SRTR data on 928 pediatric and 1814 adult LT candidates who were ever offered a splittable graft. We compared eventual mortality, regardless of subsequent transplants, between those who accepted versus declined a splittable liver offer with adjustment for PELD/MELD, diagnosis, and weight among pediatric candidates, and matching for MELD, height, and offer among adult candidates. Among pediatric candidates ≤7kg, splittable offer acceptance versus decline was associated with a 63% reduction in mortality (aHR 0.17 0.370.80 , p=0.01; 93.1% versus 84.0% one-year survival post-decision). Within one year of decline for those ≤7kg, 6.4% died and 31.1% received a whole liver transplant. Among pediatric candidates >7kg, there was no significant difference associated with acceptance of a splittable offer (aHR 0.63 1.071.82 , p=0.81; 91.7% vs 94.4% one-year survival post-decision). Within one year of decline for those >7kg, 1.8% died and 45.8% received a whole liver. Among adult candidates, splittable offer acceptance was associated with a 43% reduction in mortality (aHR 0.39 0.570.83, p=0.005; 92.2% vs 84.4% one-year survival post-decision). Within one year of decline for adult candidates, 7.9% died and 39.3% received a whole liver. Conclusion: Accepting splittable offers for SLT could significantly improve survival for small children and adults on the waitlist.
PMID: 34923725
ISSN: 1527-6473
CID: 5127812